Drugs / AGEN1423
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05632328 | Aug 2024 → Aug 2026 overdue | pancreatic ductal adenocarcinoma | Bruno Bockorny | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06300463 | Mar 2024 → Dec 2026 expected | metastasis from malignant tumor of colon | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGEN1423 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05632328 ↗ |
| Route | Intravenous | “via IV, dosage per protocol, once every 2 weeks for up to 8 weeks” NCT05632328 ↗ |